title: [Treatment of non-cystic fibrosis bronchiectasis].
abstract: Bronchiectasis is currently growing in importance due to both the increase in the number of diagnoses made as well as the negative impact that its presence has on the baseline disease that generates it. A fundamental aspect in these patients is the colonization and infection of the bronchial mucous by potentially pathogenic microorganisms (PPM), which are the cause in most cases of the start of the chronic inflammatory process that results in the destruction and dilatation of the bronchial tree that is characteristic in these patients. The treatment of the colonization and chronic bronchial infection in these patients should be based on prolonged antibiotic therapy in its different presentations. Lately, the inhaled form is becoming especially prominent due to its high efficacy and limited production of important adverse effects. However, one must not overlook the fact that the management of patients with bronchiectasis should be multidisciplinary and multidimensional. In addition to antibiotic treatment, the collaboration of different medical and surgical specialties is essential for the management of the exacerbations, nutritional aspects, respiratory physiotherapy, muscle rehabilitation, complications, inflammation and bronchial hyperreactivity and the hypersecretion that characterizes these patients.
authors.affiliation: Unidad de Neumología, Hospital General de Requena, Valencia, España. m.a.martinez@saludalia.com
authors.forename: Miguel Ángel
authors.initials: MÁ
authors.lastname: Martínez García
authors.forename: Luis
authors.initials: L
authors.lastname: Máiz Carro
authors.forename: Pablo
authors.initials: P
authors.lastname: Catalán Serra
mesh_terms: D000280:Administration, Inhalation; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001424:Bacterial Infections / Q000150:complications / Q000188:drug therapy / Q000382:microbiology; D001986:Bronchial Spasm / Q000139:chemically induced; D001987:Bronchiectasis / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology / Q000628:therapy; D001991:Bronchitis / Q000150:complications / Q000188:drug therapy / Q000382:microbiology; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D005081:Exercise Therapy; D005100:Expectorants / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D009330:Nebulizers and Vaporizers; D017410:Practice Guidelines as Topic; D011379:Prognosis; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000302:isolation & purification / Q000472:pathogenicity; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D020545:Respiratory Mucosa / Q000382:microbiology; D012138:Respiratory Therapy
chemical_list: D000305:Adrenal Cortex Hormones; D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D001993:Bronchodilator Agents; D005100:Expectorants